BioPharmSignal logoBioPharmSignal

Biotech News

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Intellia (NTLA)IntelliaFinancing

CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the pricing of an underwritten public offering of

Open original release

Related news

NTLAIntellia2026-04-27 20:01 EST

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

NTLAIntellia2026-06-13 11:30 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

TSHATaysha Gene Therapies2026-06-25 02:34 EST

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

TSHATaysha Gene Therapies2026-06-24 20:01 EST

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

EDITEditas Medicine2026-05-26 13:05 EST

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

CRSPCRISPR Therapeutics2026-03-11 11:00 EST

CRISPR Therapeutics Prices Upsized Convertible Senior Notes Offering

CRSPCRISPR Therapeutics2026-03-10 11:00 EST

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

EDITEditas Medicine2026-05-26 10:15 EST

Editas Medicine Announces Proposed Public Offering

View all latest news

Intellia

Intellia Therapeutics is a gene-editing company building in vivo and ex vivo CRISPR programs across serious genetic diseases.

Recent company news

NTLAIntellia2026-07-06 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-06-13 11:30 EST

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

NTLAIntellia2026-06-05 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-06-01 11:30 EST

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

NTLAIntellia2026-05-11 11:30 EST

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Stock data

Close
10.67 USD
Market cap
1.83B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States